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Abstract
Chromatin modifying enzymes play a critical role in cardiac differentiation. Previously, it has been shown that the targeted
deletion of the histone methyltransferase, Smyd1, the founding member of the SET and MYND domain containing (Smyd)
family, interferes with cardiomyocyte maturation and proper formation of the right heart ventricle. The highly related
paralogue, Smyd2 is a histone 3 lysine 4- and lysine 36-specific methyltransferase expressed in heart and brain. Here, we
report that Smyd2 is differentially expressed during cardiac development with highest expression in the neonatal heart. To
elucidate the functional role of Smyd2 in the heart, we generated conditional knockout (cKO) mice harboring a
cardiomyocyte-specific deletion of Smyd2 and performed histological, functional and molecular analyses. Unexpectedly,
cardiac deletion of Smyd2 was dispensable for proper morphological and functional development of the murine heart and
had no effect on global histone 3 lysine 4 or 36 methylation. However, we provide evidence for a potential role of Smyd2 in
the transcriptional regulation of genes associated with translation and reveal that Smyd2, similar to Smyd3, interacts with
RNA Polymerase II as well as to the RNA helicase, HELZ.
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Introduction
The formation of the heart is one of the most complex processes
during vertebrate development being dependent on the orches-
trated interplay of a variety of cell types and the precise
intracellular regulation of transcriptional networks [1–2]. The
complexity of its development renders the heart vulnerable to
congenital diseases, affecting 1–2% of all newborns and being the
leading cause of death in infants under 1 year [3]. Although, in
recent years considerable progress has been made in defining the
molecular mechanisms that control cardiac growth and differen-
tiation at transcriptional level, far less is known about the
epigenetic control of heart development imparted by chromatin
remodeling enzymes. It has become increasingly evident that, in
addition to the well-established roles of histone acetyltransferases
(HATs) and histone deacetylases (HDACs) in cardiac differenti-
ation, histone methyltransferases and demethylases are also
essential in both cardiac [4–6] and skeletal [7–10] muscle
development.
Functionally, methylation of lysine or arginine residues on
histone tails, similar to a plethora of other post-translational
histone modifications (e.g., phosphorylation, acetylation, SUMOy-
lation, ubiquitylation), has been shown to recruit protein
complexes affecting target gene expression at the transcriptional
level [11–12]. This complexity in histone modifications might not
only be seen as a simple code, but rather as an ingenious
chromatin ‘language’ where different biological outcomes are
defined by the combinatorial modification of basic building blocks
[13]. Additionally, in contrast to histone acetylation, lysine
residues can either be mono-, di- or tri-methylated, thereby
adding an additional level of ‘histone code’ complexity. Interfering
with the controlled action of histone methyltransferases by either
loss of function or gain of function experiments therefore often
results in a deleterious biological outcome due to disturbed
proliferation and/or differentiation. This phenomenon is not only
true for the heart [14], but can also be observed in a wide range of
other organs and cell types [15–18].
Members of the SET and MYND domain containing (Smyd)
family of proteins possess SET-dependent methyltransferase
capacity and have been shown to be involved in the transcriptional
control of cell differentiation and cell proliferation [19–21].
However, with the exception of Smyd1, little is known about the
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vertebrate development. Evidence for a critical role of Smyd
proteins during organ development was first shown by the
constitutive knockout of Smyd1/m-Bop, resulting in early embryonic
lethality due to disruption of cardiac differentiation and morpho-
genesis [14]. This finding made the Smyd proteins interesting
candidates for the control of cardiac growth and differentiation.
Subsequent reports have further indicated that Smyd -family
members are, indeed, critical regulators of cardiac as well as
skeletal muscle development [14,21–29].
We identified Smyd2 as a histone 3 lysine 36 (H3K36)
methyltransferase with highest expression in heart and brain
[20]. Functionally, methylation on H3K36 is most often associated
with actively transcribed genes [20,30–31]. Our in vitro studies,
however, revealed that Smyd2 acts as a transcriptional repressor
when bound to HDAC1 and the Sin3 repression complex [20].
More recent findings suggest that Smyd2 is also capable of H3K4
methylation when bound to Hsp90a, showing that the full
spectrum of Smyd2 impact on transcriptional regulation is still
largely unknown [32]. Furthermore, it has been shown that Smyd2
acts on non-histone targets by inhibiting the functional activity of
p53 via methylation of p53, lysine 370 [33]. Thus, several lines of
evidence support a role for Smyd2 in the regulation of
proliferation and in tumor progression [20,33–36].
Despite being highly expressed in heart and brain, a specific
functional relevance for Smyd2 in these organs has not yet been
described. To that end, we have examined its spatiotemporal
expression during vertebrate cardiac development and performed
loss of function experiments. We report quite unexpectedly that,
while Smyd2 is expressed nearly exclusively in cardiomyocytes in
high abundance around birth, its cardiac-specific deletion has no
major discernable impact on normal heart development.
Materials and Methods
Animals and cardiomyocyte isolation
This investigation conforms to the Guide for the Care and Use
of Laboratory Animals published by the US National Institutes of
Health (NIH Publication No. 85-23, revised 1996). Animal
experiments were approved by the local committee for care and
use of laboratory animals (Regierungspra ¨sidium Darmstadt, Gen.
Nr. B 2/202). Ventricular cardiomyocytes from fetal (E17), 3-days-
old (P3), and adult (.10 weeks, 200–250 g) Sprague Dawley rats
(Charles Rivers, or own breed) were isolated and cultured as
described [37–38].
Plasmids and constructs
Myc-tagged Smyd2 and Smyd3 have been described previously
[20].
Western Blot analysis
Cardiac ventricles were washed in ice-cold PBS, minced and
then homogenized and lysed by repeated sonication in cell lysis
buffer (Cell Signaling) containing 1 mM PMSF and 1x protease
inhibitor cocktail (Roche) on ice. After additional 15 min
incubation, samples were centrifuged at 17.0006ga t4 uCf o r
10 min to remove cell debris. Whole cell extracts from cultured
cells were made using the same lysis buffer. Nuclear/cytosolic
fractioning was performed using NE-PER Kit (Pierce) according
to the manufacturer’s protocol. Total histone fractions were
isolated from pooled (n=6) neonatal (P3–5) Smyd2
flox/flox or Smyd2
conditional knockout (cKO) mouse hearts using the EpiQuick
TM
Total Histone Extraction Kit (Epigentek) according to the
manufacturers protocol. Protein concentration was determined
using DC Protein Assay (Bio-Rad). Equal amounts of proteins
were resolved on 4–12% Bis-Tris Gels (Invitrogen) and blotted
onto PROTRANH nitrocellulose membranes (Whatman). Mem-
branes were blocked with 5% non-fat dry milk in Tris-buffered
saline (TBS) with 0.1% TWEEN-20 for 1 hour at RT and then
incubated with primary antibodies overnight at 4uC under gentle
agitation. Antigen-antibody complexes were visualized using
horseradish peroxidase-conjugated secondary antibodies (Amer-
sham) and SuperSignalH West Femto substrate (Thermo) on a
VersaDoc imaging system (Bio-Rad). The following antibodies
have been used: rabbit anti-Smyd2, 1:500 (Abcam), mouse anti-
PARP, 1:500 (Transduction Laboratories), mouse anti-HSP70,
1:500 (Transduction Laboratories), rabbit anti-Pan-Actin,
1:2000 (Cell Signaling), mouse anti-GAPDH, 1:4000 (SIGMA),
mouse anti-p53, 1:200 (SIGMA), rabbit anti-Troponin-I, 1:250
(Santa Cruz), rabbit anti-H3K4me1, rabbit anti-H3K4me2,
rabbit anti-H3K4me3, rabbit anti-H3K36me1, rabbit anti-
H3K36me3 (Millipore), rabbit anti-H3K36me2, rabbit anti-
H4K20me3, (Epigentek), rabbit anti-Histone H3, rabbit anti-
Histone H4, (Bethyl Laboratories). All histone antibodies were
diluted 1:1000.
Real-time qPCR and semi-quantitative RT-PCR
RNA from mouse tissue was isolated using TRIZOL (Invitro-
gen) according to standard protocols. RNA from cultured cells was
isolated using RNeasy Kit (Qiagen) including on-column DNase
digest according to the manufacturer’s protocol. For cDNA
synthesis the RNA from .10 fetal heart ventricles and $3
postnatal heart ventricles was pooled and subjected to reverse
transcription using M-MLV reverse transcriptase (SIGMA). RNA
for expression profiling in different mouse tissues was isolated from
3 male neonatal animals and pooled for cDNA synthesis. cDNA
was used for real-time qPCR or semiquantitative RT-PCR
respectively. Real-time qPCR was performed in triplicates using
Absolute
TM QPCR SYBRH Green Fluorescin Mix (Thermo
SCIENTIFIC) and Bio-Rad iCYCLER iQ5 Real time PCR
instrument. Relative gene expression was calculated on the basis of
DCt values to Gapdh or ß-actin as housekeeping genes. All primer
pairs used for real-time qPCR and RT-PCR respectively are
summarized in the supplementary information (Table S1).
Immunofluorescence staining
For cryosections P1 neonatal mouse hearts were isolated,
washed in cold PBS and then embedded in POLYFREEZE
TM
tissue freezing media (Polysciences Inc.). Embedded hearts were
frozen in methylbutane on liquid nitrogen, sectioned (transverse,
10 mM). For immunostaining cryosections or cultured cells were
fixed for 15 min in 4% formaldehyde. Permeabelization was
performed in PBS + 0.5% Triton X-100 for 10 min at RT and
blocking in 5% goat serum/0.2% TWEEN-20/PBS for 1 h at RT.
Primary antibodies were diluted in blocking solution and
incubated at 4uC for overnight. The following antibodies have
been used for immunostaining: rabbit anti-Smyd2, 1:75 (Abcam),
mouse anti-Tropomyosin, 1:100 (SIGMA), mouse anti-Caveolin-
3, 1:200 (Transduction Laboratories).
Histological analysis
The hearts from 5 day old neonatal or adult mice were dissected
and soaked in ice-cold 30 mM KCl/PBS to induce diastolic arrest,
washed and subsequently fixed in 4% paraformaldehyde,
dehydrated, embedded in paraffin and sectioned at 6 mM. Sections
were stained with hematoxylin and eosin or Masson’s trichrome
according to standard protocol and examined by light microscopy.
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MRI experiments were carried out on a 7.0 T Bruker
Pharmascan, operating at 300.51 MHz for
1H and equipped with
a 300 mT/m gradient system, using a custom-built circularly
polarized birdcage resonator and the Early Access Package for
self-gated cardiac Imaging (Intragate, Bruker, Ettlingen, Germany)
[39]. The measurement is based on a gradient echo method; the
imaging parameters are: echo time/repetition time=44.4/6.3 ms;
flip angle=15u; field of view=2.2062.20 cm; slice thick-
ness=1.0 mm; matrix=1286128; repetitions=100. The imaging
plane was localized using scout images showing the 2- and 4-
chamber view of the heart, followed by acquisition in short axis
view, orthogonal on the septum in both scouts. Multiple
contiguous short-axis slices consisting of 6 to 7 slices were
acquired for complete coverage of the left ventricle. MRI data
were analyzed using Qmass digital imaging software (Medis,
Leiden, Netherlands). All mice were measured under volatile
isoflurane (1.5 to 1.7%) anesthesia and body temperature was
maintained at 37uC throughout the measurements. For measure-
ment 4 male Smyd2
fl/fl animals were used as control group
compared to 4 male Smyd2 cKO animals, all 6 months old.
Cloning of the Smyd2 conditional targeting construct
and generation of Smyd2 conditional knockout mice
To construct the Smyd2 conditional targeting construct, two
genomic fragments were first subcloned from the C57BL/6
murine Bac clone-RPC124288J3. A 2.2 kb KpnI fragment
containing exon 1 and a KpnI fragment containing 5.2 kb of
intronic sequence between exons 1 and 2 was subcloned into
pBluescript (Stratagene). Fragment 1 (5.2 kb) was excised with
KpnI, blunt ended, and ligated into the unique blunt ended SalI
site of pDELBOY [40]. The resulting clones were screened for
correct orientation and for the regeneration of the SalI site.
Fragment 2 (2.2 kb) was excised with KpnI and ligated into the
unique KpnI site of pDELBOY containing fragment 1. This was
subsequently screened for correct orientation. Fragment 3,
containing 0.6 kb upstream of exon 1, was generated using
Platinum Pfx DNA Polymerase (Invitrogen), C57BL/6 genomic
DNA as template, and the following primer pair 59gtcgacattgagc-
taatgtgctta-39and 59-ctcgaggtaacactcaacctctgc-39. The resulting
PCR product was treated with Taq Polymerase, ligated into
pGEM-T EASY (Promega), and excised with SalI and XhoI. This
product was ligated into the unique XhoI site of pDELBOY
containing fragments 1 and 2 and subsequently screened for
correct orientation. The completed targeting construct was
linearized at the short arm of homology using XhoI. C57BL/6
ES cells were then transfected and selected with G418 and
gancyclovir. Targeted ES cell colonies were screened by Southern
hybridization analysis using probes specific for the genomic
sequence external to the arms of homology. The 59 Southern
used a 0.8 kb PCR fragment using the following primer pair: 59-
ggctggagttagaggtggttatga-39and 59-acagctctgggctcggaaataaag-39.
The 39 Southern used a 0.9 kb PCR fragment using the following
primer pair: 59-aactccatgtggtggaattctgtggt-39and 59-gcagcctgaaa-
gaatcccttagact-39. Successfully targeted ES cells were identified by
Southern analyses. These assays were performed across the long
arm of homology and the short arm of homology of clones that
had experienced homologous recombination at the Smyd2 locus. A
size difference allowed the separation of targeted allele and wild
type allele. These clones were then injected into C57Bl/6J-tyr-2J
(an albino strain) blastocysts, which were implanted into the uteri
of psuedopregant recipients and ultimately chimeras were born.
The chimeras were mated to albino C57Bl/6 females and resulting
progeny with a black coat color were genotyped. Mice that were
shown to be heterozygous for the targeted allele were mated to
Flip recombinase-expressing transgenic mice to remove the neo
cassette. Targeted deletion of Smyd2 in cardiac tissue was
accomplished by crossing mice expressing Cre recombinase under
the control of the Nkx-2.5 promoter as described previously [41]
into Smyd2 homozygous floxed mice and backcrossing the resulting
heterozygous mice governing the Cre recombinase back to
homozygous Smyd2
flox/flox mice. Cre mediated recombination
resulted in a deletion of a region including exon 1 of Smyd2.
Microarray analysis
RNA was isolated from postnatal day 5 (P5) Smyd2
flox/flox or
Smyd2
flox/floxCre mouse cardiac ventricles (n=4/4) according to
standard TRIZOL protocol (Invitrogen). RNA quality was
assessed using Agilent 2100 Bioanalyzer and RNA 6000 Nano
Kit (Agilent). For mRNA expression analysis, the Affymetrix
GeneChip Mouse Gene 1.0 ST Array was employed with the
Affymetrix total RNA labeling protocol. Data were analyzed by
the RMA algorithm using the Affymetrix Expression Console.
Annotation and statistical analysis were performed with the
DNAStar
TM Arraystar
TM 3.0 software using log2 transformed
data. Fold changes were calculated on the basis of the median of
signal intensity of the groups. To maximize the number of true
positives, unpaired t-test without further correction was used for
statistical analysis. Microarray data is deposited in MIAME
compliant format at the ArrayExpress Database (http://
www.ebi.ac.uk/microarray) with the assigned accession number:
E-MEXP-2542.
Statistical analysis
Results were analysed by GraphPad Prism (version 4.00,
GraphPad Software Inc.). Statistical significance was determined
using a Student’s t-test. Values of P,0.05 were considered
statistically significant.
Results
Temporal expression profiling of Smyd-family members
during cardiac development
To determine the temporal expression patterns of Smyd-family
members during vertebrate heart development, we collected
mouse cardiac ventricles at sequential developmental stages from
embryonic (E) days 12.5 to 18.5, postnatal (P) days 1 to 7 and adult
and determined the relative mRNA expression levels of Smyd1-5.
Smyd1 and Smyd2 showed distinct expression in cardiac ventricles
with peak mRNA expression between P1 and P5 displaying a
.10-fold and .5-fold developmental change respectively. In
contrast, Smyd5 expression changed less than 3-fold and peaked
before birth (Fig. 1A). Smyd3 and Smyd4 expression was almost
undetectable at any given time point (data not shown).
Since Smyd2 expression has not yet been described in the
neonatal heart and previous expression analyses were only
performed at the mRNA level using Northern-blotting and in situ
hybridization [20], we next investigated Smyd2 protein expression
in heart ventricles during cardiac development. Western-Blot
analysis showed relatively high Smyd2 protein expression in P1
cardiac ventricles while very low expression was detected at E12.5
and adult. This expression pattern was conserved between rat and
mouse (Fig. 1B).
As Smyd2 expression in the heart peaks shortly after birth, we
re-evaluated Smyd2 expression in other organs at that time as our
previous evaluation was performed only in adult mouse organs
where Smyd2 expression is almost absent [20]. In line with our
previous findings, Smyd2 showed a broader organ distribution
Smyd2 in Heart Development
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heart, skeletal muscle and brain tissue. In contrast, Smyd5
expression levels were uniform in all analyzed organs (Fig. 1C).
Smyd2 is specifically expressed in cardiomyocytes
In order to obtain deeper insight into the cell type-specific
expression characteristics of Smyd1, 22 and 25 in the heart, we
isolated RNA from either non-cardiomyocyte (non-CM) or
cardiomyocyte (CM) fraction from neonatal (P3) rat heart
ventricles and performed semiquantitative RT-PCR. Fraction
purity was determined using primer pairs that specifically amplify
transcripts of the cardiac marker gene Nkx.2–5. Interestingly,
Smyd1 and 22 were almost exclusively expressed in cardiomy-
ocytes while, in accordance with its organ distribution, Smyd5
exhibited relatively uniform expression in CM and non-CM
fractions (Fig. 2A). Smyd3 and 24 did not show significant
expression in either fraction (data not shown).
The observed cardiomyocyte-specific expression of Smyd2 was
further analyzed at the protein level. Western-blots confirmed the
distinct Smyd2 protein expression in the Troponin-I positive
cardiomyocytes (Fig. 2B).
Since Smyd proteins have been shown to modify both histone [20]
and non-histone [33] targets, we next investigated the cellular
localization of Smyd2 in cardiomyocytes. Western-blot analysis of
nuclear and cytosolic extracts from neonatal (P3) rat cardiomyocytes
revealed that Smyd2 protein is expressed in nuclear as well as
cytosolic cell fractions. The specific fraction marker proteins PARP
(nucleus) and HSP70 (cytosol) were used to confirm the purity of the
fractions (Fig. 2C). In line with western blot results, this subcellular
distribution was also observed using immunocytochemistry (Fig. 2D).
Taken together, the data indicate that Smyd1 and Smyd2 are
the only Smyd-family members observed to be preferentially
expressed in cardiomyocytes, and their levels are markedly
regulated during cardiac development.
Figure 1. Temporal expression patterns of Smyd-family members during vertebrate heart development. (A) Real-time qPCR showing
relative expression levels of Smyd-family members in mouse heart ventricles at different developmental stages (E12.5 to adult as indicated).
Expression levels of Smyd-family members were normalized to GAPDH Ct values as housekeeping gene. qPCR analysis of Smyd-family members 21,
22 and 25 reveals a peak mRNA expression for Smyd1 and Smyd2 between postnatal day 1 to day 5 while Smyd5 mRNA shows highest expression
levels during embryonic stages E14.5 to E18.5 ceasing after birth. (B) Western-blots of pooled E12.5, P1 or adult tissue extracts (70 mg) from rat and
mouse heart ventricles were probed with anti-Smyd2 antibody showing maximal expression at postnatal day 1. Blots were re-probed with anti-
GAPDH antibody for equal loading control. (C) Semiquantitative RT-PCR for Smyd1, 22 and 25 expression in neonatal (P4) mouse tissues. 18s rRNA
expression was used as loading control.
doi:10.1371/journal.pone.0009748.g001
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Since Smyd2 expression is not restricted to the heart (Fig. 1C),
we generated mice that allow the tissue specific deletion of Smyd2
expression. For this purpose we generated Smyd2 homozygous
floxed mice (for detailed description see Materials and Methods).
In brief, the targeting vector contained a short (0.6 kb) and a long
(7.4 kb) arm of homology, a neomycin resistance cassette (neo) for
positive selection, and a thymidine kinase cassette for negative
selection. LoxP sites were positioned in a region including exon 1
of Smyd2 (Fig. 3A).
Targeted ES cell colonies were screened by Southern
hybridization analysis using probes specific for the genomic
sequence external to the arms of homology. These assays were
performed across the long arm of homology (Fig. 3B) using SalI
Figure 2. Smyd2 is predominantly expressed in cardiomyocytes. (A–B) RNA and protein was isolated from either non-cardiomyocyte (non-
CM) or cardiomyocyte (CM) fraction following digestion of P3 rat heart ventricles. (A) Semi-quantitative RT-PCR was performed using primer pairs
specifically detecting Smyd1, 22 and 25. Using RNA as a template served as negative control (-RT control). Smyd1 and Smyd2 show distinct
expression predominantly in the cardiomyocyte fraction while Smyd5 is expressed in both fractions. The expression of the cardiac marker gene
Nkx.2–5 was analyzed as a fraction purity control, GAPDH is shown as equal loading control. (B) Protein (50 mg) from non-cardiomyocyte and
cardiomyocyte fractions was subjected to Western-blotting and blots were probed with anti-Smyd2 antibody showing a predominant expression of
Smyd2 in the cardiomyocyte fraction. The membrane was re-probed with an antibody against cardiac Troponin-I as a control for fraction purity as
well as anti-pan-actin antibody for controlling equal loading. (C) Nuclear and cytosolic fractions were assessed from P3 rat cardiomyocytes and equal
protein amounts (50 mg) were subjected to Western-blotting. Smyd2 was detectable in nuclear as well as cytosolic fractions using anti-Smyd2
antibody. Blots were re-probed with antibodies against Poly (ADP-Ribose) Polymerase (PARP) as a nuclear marker protein or Heat shock protein 70
(Hsp70) as a cytosolic marker protein to assure fraction purity. (D) Immunocytochemistry using an anti-Smyd2 antibody shows that Smyd2 is
expressed in the nuclei as well as in the cytoplasm of cultured P3 rat cardiomyocytes (red). Cardiomyocytes were co-stained using an antibody
against cardiac Tropomyosin (green), nuclei were stained with DAPI (blue).
doi:10.1371/journal.pone.0009748.g002
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using BamHI for restriction to select clones that had experienced
homologous recombination at the Smyd2 locus. Mice that were
shown to be heterozygous for the targeted allele were mated to
Flip recombinase-expressing transgenic mice to remove the neo
cassette. Genotyping PCR was performed using a primer pair
binding at positions P1 and P2 (Fig. 3A) to identify WT (366 bp)
and floxed (500 bp) Smyd2 alleles, respectively (Fig. 3D).
Deletion of Smyd2 in cardiomyocytes
Targeted deletion of Smyd2 in cardiomyocytes was accom-
plished by initially crossing mice expressing the Cre-recombinase
under the control of the cardiac specific Nkx2–5 promoter [41]
with Smyd2 homozygous floxed mice (Smyd2
fl/fl). Smyd2
fl/fl mice
were mated with Smyd2
wt/fl mice harboring the Nkx2–5/Cre
transgene (Smyd2
wt/flCre) to obtain Smyd2 conditional knockout
(cKO) mice (Smyd2
fl/flCre). This mating resulted in offspring of 4
Figure 3. Generation of Smyd2 conditional knockout mice. (A) The targeting vector contains a short (0.6 kb) and a long (7.4 kb) arm of
homology, a neomycin resistance cassette (neo) for positive selection, and a thymidine kinase cassette for negative selection. Two site-specific
recombination sites were employed in vivo. Flp recombinase was used to delete the neo marker from the mouse germline and Cre recombinase
afterwards allowed the conditional deletion Smyd2 in selected tissues. Two loxP sites flank the region to be deleted. This region includes exon 1 of
Smyd2. (B–C) Southern-blot analysis was performed to identify successfully targeted ES cell clones. Wild type (wt) or targeted (ta) alleles are
indicated by arrows respectively. (B) Southern-blot analysis for homologous recombination was performed across the long arm of homology
identifying clones 7 and 9 for successful recombination by size difference. (C) Southern-blot analysis for homologous recombination was
performed across the short arm of homology also identifying clones 7 and 9 for successful recombination by size difference. The restriction
enzymes used for Southern blotting were SalI/Bgl2o rBamHI as indicated below the blots. (D) Genotyping PCR was performed using a primer pair
binding at positions P1 and P2 (A) to ide n t i f yW T( 3 6 6b p )a n df l o x e d( 5 0 0b p )Smyd2 alleles respectively. A representative genotyping PCR results
for each genotype is shown (D).
doi:10.1371/journal.pone.0009748.g003
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fl/fl, Smyd2
wt/fl, Smyd2
fl/flCre, Smyd2
wt/flCre). As
shown in figure 4A, animals were born at normal Mendelian ratios
and survived until adulthood without any obvious abnormalities.
For all subsequent analyses we used the Smyd2
fl/fl genotype as the
control group, as this is widely accepted [42–44]. The genotypes
used for analysis are shown by a representative genotyping PCR
Figure 4. Analysis of cardiac specific Smyd2 deletion. (A) Mating of Smyd2
fl/fl mice with Smyd2
fl/flCre mice resulted in offspring of four
genotypes (Smyd2
wt/fl, Smyd2
fl/fl, Smyd2
wt/flCre, Smyd2
fl/flCre) at normal Mendelian ratios. (B) The genotype of the animals used for analysis is shown by
a representative genotyping PCR. Animals homozygous for the floxed Smyd2 allele but lacking the Nkx2–5 driven Cre recombinase were used as
control. (C) Protein extracts (70 mg) from Smyd2f
l/fl, Smyd2
wt/flCre or Smyd2
fl/flCre (cKO) mouse hearts were subjected to western-blot analysis and the
knockdown efficiency as well as antibody specificity was assessed by probing the blot with an anti-Smyd2 antibody. Smyd2 protein expression was
lowered by half in the heterozygous animals while it was almost completely absent in the homozygous cKO animals. The blot was re-probed with an
anti-GAPDH antibody for equal loading control. (D) Cryosections from P1 control or Smyd2 cKO mice were stained with an anti-Smyd2 antibody (red)
and an anti-Caveolin-3 antibody (green) to co-stain the cardiomyocyte cell membrane. Smyd2 shows a distinct expression in the cardiomyocytes of
control mice while no expression was observed in the cardiomyocytes of cKO animals. Pictures were taken at a magnification of 10006. (E) Real-time
qPCR showing relative expression levels of Smyd-family members 1–5 in P5 control or Smyd2 cKO mouse heart ventricles. Data is shown as mean +/2
SEM, *p,0.05 vs. control, #p,0.01 vs. control, n=5.
doi:10.1371/journal.pone.0009748.g004
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Smyd2 protein expression in Smyd2
fl/wtCre mice was approximately
reduced by half, whereas Smyd2 expression was almost completely
abolished in cKO (Smyd2
fl/flCre) animals (Fig. 4C). Immunohisto-
chemistry using cryosections from neonatal (P1) mouse hearts
further confirmed loss of Smyd2 expression in cKO animals
(Fig. 4D).
Since the loss of Smyd2 functional activity might result in
compensation by other Smyd-family members, we also investigat-
ed whether expression levels of the related Smyd genes 1–5 are
affected by Smyd2 deletion. Relative Smyd1–5 mRNA expression
profiles in hearts from P5 mice were obtained using real-time
qPCR of RNA/cDNA samples from either control or Smyd2 cKO
mice. This analysis confirmed the significant knockdown of Smyd2
expression and revealed that Smyd1/mBop expression was
modestly, but statistically significantly, elevated (1.3-fold60.09)
in the cKO animals. No significant changes were detected for
other Smyd transcripts (Fig. 4E).
Morphologic and functional analysis of Smyd2 cKO hearts
Following successful knockdown of Smyd2 in cardiomyocytes
we analyzed the hearts of adult Smyd2 cKO mice. The Smyd2 cKO
hearts appeared normal (Fig. 5A), and we detected no significant
changes in heart to body weight ratios compared to control mice at
6 month of age (Fig. 5B). Similar results were obtained from
analyses of neonatal hearts (data not shown).
Since Smyd2 is most highly expressed after birth, we also
examined the hearts of neonatal (P3) as well as adult (.8 weeks)
mice by histological analysis using hematoxylin and eosin staining
as well as Masson’s trichrome staining. Upon microscopic
observation we observed no obvious differences in necrosis or
cardiomyocyte organization (Fig. 5C). Additionally, no signs of
cardiac fibrosis were observed (Fig. 5D).
The absence of morphological changes would not rule out
potential phenotypes at the functional level. Thus, we assessed
functional cardiac parameters by MRI-analysis. As shown in
Fig. 5E, Smyd2 deficiency did not alter end-systolic volume, end-
diastolic volume or stroke volume compared to control littermates.
Observed variations in functional parameters deviate in physio-
logic range [45].
Taken together, the data suggest that Smyd2 does not
contribute non-redundantly to development or maintenance of
normal cardiac morphology even though neonatal cardiomyocytes
are the primary site of Smyd2 expression.
Molecular analysis of Smyd2 cKO hearts
In an attempt to reconcile these paradoxical findings, we
investigated potential genome-wide changes in the cardiac
transcriptome by expression profiling. Based on the observation
that Smyd2 expression peaks after birth, we expected maximal
changes in target gene expression between Smyd2 cKO and control
animals at that time. Yet, microarray analyses of neonatal (P5)
heart ventricles revealed only modest changes in global gene
expression patterns (ArrayExpress/accession no.: E-MEXP-2542).
Although Smyd2 was previously shown to function as a
transcriptional repressor in cultured cells [20], the vast majority
(79%) of the differentially expressed transcripts were down-
regulated (Fig. 6A). Functional annotation analysis for all
significantly regulated transcripts [46–47] indicated that regulated
transcripts are enriched in translational processes (p-value ,0.01)
(Fig. 6B). Interestingly, the majority of enriched transcripts in this
cluster were found to encode for subunits of either cytosolic or
mitochondrial ribosomes. Real-time qPCR was performed as a
second technique to additionally confirm transcriptional regula-
tion of certain mitochondrial ribosomal subunits (Fig. 6C).
The majority of deregulated genes in Smyd2 cKO hearts
displayed reduced expression. This, along with the observation
that Smyd2 gain of function experiments, in vitro, resulted in a
predominant up-regulation rather than down-regulation of genes
[32], predicted that Smyd2 might act as a transcriptional activator
in the wild type heart. As Abu-Farah and colleagues found histone
methyltransferase activity to be essential for target gene upregula-
tion [32], we also determined the extent of H3K4 as well as
H3K36 methylation in neonatal Smyd2 cKO versus control hearts,
as these histone modifications are generally believed to be
associated with actively transcribed genes [30–31,48–49]. How-
ever, western blot analyses using purified histone fractions revealed
no differences in the extent of mono-, di- or tri-methylation on
H3K36, or H3K4 (Fig. 6D).
An alternative mechanism by which Smyd2 might contribute to
transcriptional activation was suggested in previous studies of the
highly related paralogue, Smyd3 [19]. In addition to catalyzing
H3K4 HMTase activity, Smyd3 may act as a direct transcriptional
regulator via a ternary association with RNA Polymerase II and
the RNA helicase, HELZ [19]. As with Smyd3, Smyd2 co-
immunoprecipitates with co-transfected HELZ as well as with
endogenous RNA polII (Fig. 6E, F). This feature, shared by
Smyds2 and 3, might contribute to the observed target
deregulation observed in our microarrays in the absence of global
methylation changes.
Discussion
Members of the Smyd protein family have been shown to be
involved in the regulation of cellular differentiation processes
[19–21]. It has become increasingly apparent that the functional
role of Smyd proteins is of particular importance for the
differentiation of muscle tissue [14,25–27,29]. Targeted gene
disruption revealed Smyd1 to be essential for early cardiac
development [14] by acting as a downstream effector of the
cardiac transcription factor, MEF2C, in the developing heart [26].
However, functional characterization of other Smyd-family
members in the heart has not been performed. Since we have
recently identified Smyd2 as a distinct Smyd -family member that
is most highly expressed in heart and brain [20], we performed a
study aimed at expanding the understanding of Smyd proteins in
the heart with specific focus on Smyd2.
Our results reveal that Smyd2 is differentially expressed during
cardiac development, displaying highest expression levels around
birth in rats and mice. In contrast to Smyd1 deficiency, loss of
Smyd2 does not result in embryonic lethality, consistent with
implications from expression data that Smyd2 functions later in
development. Smyd2 cKO animals are viable and are born in
normal Mendelian ratios with no obvious changes in heart
morphology or function. Thus, Smyd2 does not appear to be
essential for early heart formation.
Given a peak expression of Smyd2 in the first week of postnatal
life, one might anticipate that Smyd2 is important for the
biological processes occurring during this time period, namely
the irreversible exit from cell cycle [50–52] as well as the change
from mainly lactate and glucose catabolism to mitochondrial fatty
acid oxidation [53]. If Smyd2 was essential for these processes, we
would have expected deregulation of genes associated with either
cell cycle control (cyclins, CDKs, cell cycle inhibitors) or key
regulatory enzymes for cardiac energy metabolism, such as carnitine
palmitoyl transferase-I or medium-chain acyl-CoA dehydrogenase [54].
However, microarray analyses did not reveal significant changes of
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PLoS ONE | www.plosone.org 8 March 2010 | Volume 5 | Issue 3 | e9748Figure 5. Morphologic analysis of Smyd2 cKO hearts. (A) The hearts from 6 month old Smyd2
fl/fl or Smyd2 cKO animals were isolated and
washed in cold 30 mM KCl/PBS. Subsequently photographs were taken using a standard digital camera. Scale bar indicates 1 cm. (B) Heart to body
weight ratios were obtained from adult male Smyd2
fl/fl or Smyd2 cKO animals. Data is shown as means 6 SEM, n=4. (C) Tissue sections from neonatal
(P3) or adult (.8 weeks) male Smyd2
fl/fl or Smyd2 cKO hearts were examined by histological analysis with hematoxylin and eosin staining (H&E). No
signs of necrosis or cardiomyocyte disarray have been observed. Scale bar=65 mm, n=4. (D) Tissue sections from neonatal (P3) or adult (.8 weeks)
male Smyd2
fl/fl or Smyd2 cKO hearts were examined by Masson’s trichrome staining. Signs of fibrosis were not observed in cardiac ventricles. Scale
bar=65 mm, n=4. (E) Functional cardiac parameters were obtained using MRI analysis of either male Smyd2
fl/fl or Smyd2 cKO mice at the age of 6
month. No statistical differences were detected for end-systolic, end-diastolic or stroke volume. Data is shown as means 6 SD, n=4.
doi:10.1371/journal.pone.0009748.g005
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PLoS ONE | www.plosone.org 9 March 2010 | Volume 5 | Issue 3 | e9748Figure 6. Molecular analysis of Smyd2 cKO hearts. (A–B) Microarray analysis was performed on RNA from P5 neonatal Smyd2
fl/fl or Smyd2 cKO
mouse heart ventricles (4 animals per genotype) and sorted for significantly regulated transcripts (p-value ,0.05). (A) Significantly regulated
transcripts have been sub grouped by either up- or down-regulation compared to the Smyd2
fl/fl control group. (B) Gene ontology analysis was
performed on significantly regulated transcripts using DAVID tool (http://david.abcc.ncifcrf.gov/). Significantly enriched biological processes are
shown and plotted as the 2log(p-value). (C) Real-time qPCR analysis of 3 nuclear encoded genes for mitochondrial ribosomal subunits was
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PLoS ONE | www.plosone.org 10 March 2010 | Volume 5 | Issue 3 | e9748such marker genes in P5 mouse heart ventricles, nor did adult
Smyd2 cKO hearts exhibit differences in size or weight as would
have been expected if the proliferation of cardiomyocytes was
affected [55]. Surprisingly, we found that the majority of genes
affected by cardiac Smyd2 deletion are functionally associated
with translation. Interestingly, a number of the down regulated
genes (eg, Mrpl45, Mrps18a and Mrpl3) belong to the nuclear
encoded repertoire of mitochondrial ribosomal subunits [56–58].
To our knowledge there are no previous data showing a
transcriptional increase in components of the translational
machinery occurring after birth. Nonetheless, our results suggest
that the hypertrophic growth of the heart just after birth might be
facilitated by a temporary increase in protein translation. Such a
phenomenon is consistent with previous results which demon-
strated increased ribosome expression during pathologic hyper-
trophy of cardiomyocytes (for review see Hannan et al. [59]). The
fact that we do not observe hypertrophy suggests that Smyd2 is not
a key regulator of normal growth. It will, however, be of interest to
test how Smyd2 cKO mice react to stress.
We and others have previously characterized Smyd2 as a
histone methyltransferase with capacity to methylate H3K36 [20]
as well as H3K4 [32]. As these findings were based on in vitro as
well as cell culture studies, our current study provided the
opportunity to test whether corresponding effects could be
observed in vivo. The observed absence of any detectable changes
in global H3K36 or H3K4 methylation, while unexpected,
indicates that redundant HMTases might compensate in the
developing heart. In particular, Smyd1, also has H3K4 methyl-
transferase activity [25]. Since Smyd1 expression is slightly (but
statistically significantly) elevated upon Smyd2 deletion, it is
possible that this function of Smyd2 might be partially compen-
sated by Smyd1. An alternative and trivial explanation might be
that Smyd2 is predominantly expressed in cardiomyocytes which
make up only 56% of all cell types in the murine heart [60].
Assuming that Smyd2 might be involved in the transcriptional
regulation of a subset of target genes in cardiomyocytes, one might
not expect to detect global changes in histone methylation using
crude heart tissue by western blot techniques. Therefore, a more
detailed analysis of histone methylation status on isolated murine
cardiomyocytes at confirmed target site promoters will be
conducted in future experiments.
The finding that most of the deregulated genes in Smyd2 cKO
hearts were repressed indicate a role for Smyd2 as an activator in
the developing heart. This is consistent with other data from
overexpression studies, showing that Smyd2 gain of function
predominantly results in the up-regulation of genes [32]. The
finding that Smyd2 is capable of interacting with RNA Polymerase
II as well as the RNA helicase, HELZ, suggests that Smyd2 might
share functional similarities with Smyd3 [19]. Although we do not
provide evidence for a functional consequence of the interaction
between Smyd2 and RNAPolII or HELZ regarding the regulation
of transcription, one might speculate that Smyd2 might also
facilitate target gene expression via the elongation of transcription.
In addition to its molecular function as a histone methyltrans-
ferase, Huang et al. recently proposed a distinct role for Smyd2 as a
putative oncogene by methylating p53 and thereby repressing its
tumor suppressive function [33]. Although we did not specifically
address the functional consequence of Smyd2 deficiency for p53
activityinvivo,one mighthaveexpected apronouncedphenotype,at
least in adult Smyd2 cKO animals. This seemed reasonable, as it
has been shown that cardiac deletion of Mdm4, another inhibitor of
p53 functional activity, results in p53-dependent dilated cardiomy-
opathy [61]. However, functional misregulation of p53 by Smyd2 in
vivo seems unlikely for the heart, as Smyd2 cKO hearts showed no
noticeable change in the levels of apoptosis or necrosis, nor
transcriptional changes in the p53 target genes Mdm2 and p21
(Figure S1A). Additionally we did not observe any differences in p53
protein stability (Figure S1B/C). Given the importance of
understanding the precise mechanisms of p53 regulation in vivo,
our Smyd2 cKO mice will provide a useful tool for gathering such
information in the heart as well as other organs. The relevance of
Smyd2 in the heart will be particularly interesting in regard to stress
models(myocardial infarction, hypoxia), as functional misregulation
of p53 and other stress sensors might be masked under physiologic
conditions, becoming apparent only when an acute need is present.
In summary, our data reveal that Smyd2 is dispensable for
cardiac development and maturation in the mouse under normal
physiologic conditions. They further suggest that Smyd2 might be
involved in the transcriptional regulation of genes associated with
protein translation.
Supporting Information
Table S1
Found at: doi:10.1371/journal.pone.0009748.s001 (0.04 MB
DOC)
Figure S1 Regulation of p53 target genes in Smyd2 cKO hearts
(A) Microarray analysis was performed on RNA from P5 neonatal
Smyd2fl/fl or Smyd2 cKO mouse heart ventricles. Transcriptional
changes were analyzed for the p53 target genes Mdm2 and p21.
Data is given as fold changes versus Smyd2flox/flox and shown as
means 6 SD, n=4. (B) Protein extracts (50 mg) from P3 Smyd2fl/
fl or Smyd2 cKO mouse hearts were subjected to western-blot
analysis and blots were probed with an anti-p53 antibody. Blots
were re-probed with an anti-GAPDH antibody for equal loading
control. A representative blot is shown. No differences in p53
protein expression were observed. (C) Densitometric analysis of
p53 protein expression using western-blot. Data is shown as
means 6 SEM and ratio to GAPDH, n=3.
Found at: doi:10.1371/journal.pone.0009748.s002 (0.54 MB
TIF)
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